Transgenomic Q1 Revenues Slide 15 Percent | GenomeWeb

NEW YORK (GenomeWeb News) — Transgenomic said after the close of the market on Wednesday that its first quarter revenues declined 15 percent year over year.

For the three months ended March 31, the Omaha, Neb.-based molecular diagnostics firm logged total revenues of $6.3 million compared to $7.4 million in the prior-year period. Transgenomic attributed this decline primarily to lower sales in its Laboratory Services segment, reflecting higher-than-usual sales in Q1 2013 that had resulted from working down a backlog of Nuclear Mitome tests from 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.